--- title: "Depo Provera Meningioma Lawsuit: Brain Tumor Claims Guide" url: https://www.masstortmarketingagency.com/blogs/depo-provera-meningioma-lawsuit canonical: https://www.masstortmarketingagency.com/blogs/depo-provera-meningioma-lawsuit published: 2026-02-05 modified: 2026-02-05 author: name: Tarun role: Founder, Mass Tort Agency publisher: name: Mass Tort Agency url: https://www.masstortmarketingagency.com description: | The connection between Depo-Provera (medroxyprogesterone acetate) injections and meningioma brain tumors: the French ANSM study showing a 5.6x increased risk for one year or more of use, FDA and international regulatory actions, Pfizer failure-to-warn liability, qualification criteria, and litigation strategy for plaintiff firms. keywords: - Depo-Provera meningioma lawsuit - medroxyprogesterone acetate - brain tumor claims - ANSM study 5.6x risk - Pfizer failure to warn - progesterone receptor meningioma license: | Cite freely with attribution to Mass Tort Agency. Verbatim quoting permitted with citation back to the canonical URL. --- # Depo-Provera meningioma lawsuit: brain tumor claims guide > **Quick answer.** A French ANSM study published in the BMJ found that > women who used Depo-Provera (medroxyprogesterone acetate) for one year > or longer had a 5.6 times higher risk of developing intracranial > meningioma requiring surgery. Approximately 60–80% of meningiomas > express progesterone receptors, the biological pathway for the drug's > tumor-promoting effect. Pfizer — which acquired Pharmacia & Upjohn in > 2003 — is the primary defendant on failure-to-warn theories. The > litigation is in its early stages, with MDL consolidation underway or > anticipated. ## Understanding the Depo-Provera meningioma lawsuit: an overview for attorneys Depo-Provera (medroxyprogesterone acetate, or MPA) has been one of the most widely prescribed injectable contraceptives in the United States since its FDA approval in 1992. Administered as an intramuscular injection every three months, it has been used by millions of women. A growing body of scientific evidence now links prolonged use to an increased risk of meningioma — a brain tumor arising from the meninges, the protective membranes surrounding the brain and spinal cord. Women who developed meningioma after Depo-Provera injections are pursuing claims against Pfizer (which acquired Pharmacia & Upjohn, the original manufacturer) alleging the company knew or should have known about the risk and failed to warn. > The Depo-Provera meningioma litigation combines a 5.6-fold risk increase, strong biological plausibility, and international regulatory precedent — creating one of the most scientifically compelling mass tort opportunities in the pharmaceutical space. ## What is meningioma? Understanding brain tumors linked to Depo-Provera Meningiomas develop from the meningeal cells of the arachnoid layer surrounding the brain and spinal cord. They are the most common primary brain tumor, accounting for approximately 40% of all primary intracranial tumors. The World Health Organization classifies them in three grades: | WHO Grade | Classification | Frequency | Recurrence risk | |---|---|---|---| | I | Benign | ~80% | Low | | II | Atypical | ~15–18% | Moderate | | III | Anaplastic / Malignant | ~2–4% | High | Even Grade I "benign" tumors can cause significant neurological symptoms due to size and location. ### Symptoms and clinical impact Common symptoms include persistent headaches, vision changes, hearing loss or tinnitus, seizures, cognitive changes (memory problems, confusion, personality changes), weakness in the extremities, and speech difficulties. Treatment often requires craniotomy — surgical removal through an opening in the skull — with risks including bleeding, infection, neurological damage, and cognitive impairment. Radiation therapy may follow for tumors that cannot be fully resected or that recur. Many patients face lifelong monitoring, repeat surgeries, and lasting deficits. ## Medroxyprogesterone acetate: the mechanism behind meningioma development ### Hormonal receptor expression in meningiomas Studies report progesterone receptor positivity in approximately 60–80% of meningiomas. This receptor expression provides the biological pathway through which exogenous progestins like MPA can stimulate meningeal cell growth and tumor development. ### How Depo-Provera promotes tumor growth MPA binds to progesterone receptors on meningeal cells, activating proliferation pathways. Unlike natural progesterone, which fluctuates with the menstrual cycle, Depo-Provera delivers a sustained, high dose of synthetic progestin throughout the three-month injection interval. The dose-response relationship is critical: longer use means greater cumulative progestin exposure and higher meningioma risk — a biological gradient consistent with causation rather than mere statistical association. ## The French ANSM study: landmark research showing 5.6x increased risk The most significant epidemiological evidence is a large population-based cohort study conducted under the French National Agency for the Safety of Medicines and Health Products (ANSM) and published in the BMJ, analyzing health records of hundreds of thousands of women. Key findings: - Women using injectable medroxyprogesterone acetate for **one year or longer had a 5.6 times higher risk** of intracranial meningioma requiring surgery versus never-users — statistically significant and robust after adjusting for confounders. - A **dose-response relationship**: women using Depo-Provera for three or more years had even higher risk elevations. - The increased risk **diminished after discontinuation**, further supporting causation. ## FDA safety communications and regulatory response ### Historical FDA posture Depo-Provera initially faced significant regulatory resistance — the FDA rejected multiple applications before approving it as a contraceptive in 1992, decades after development. The FDA has required label changes over the years, including a 2004 Black Box Warning for bone mineral density loss, but meningioma risk was not addressed in FDA labeling for decades despite emerging evidence. ### Recent actions The FDA has issued safety communications acknowledging the potential meningioma risk and has been evaluating whether label changes are necessary. Internationally, French health authorities mandated specific meningioma warnings and recommended limiting duration of use following the ANSM study; the European Medicines Agency has also evaluated the evidence. These international actions matter in U.S. litigation because they show regulators worldwide found the evidence compelling enough to warrant warnings not provided to American women. ## Pfizer and Pharmacia & Upjohn: manufacturer liability ### Corporate history The drug was developed by The Upjohn Company, which merged with Pharmacia to form Pharmacia & Upjohn. In 2003, Pfizer acquired Pharmacia and assumed responsibility for Depo-Provera. As current manufacturer and marketer, Pfizer bears primary responsibility for the adequacy of warnings. ### Legal theories - **Failure to warn (central theory):** Pfizer and predecessors knew or should have known about the meningioma association from the scientific literature, the biological mechanism, and data on related progestational agents, yet failed to include adequate warnings in prescribing information, patient medication guides, or marketing materials. - **Design defect:** the formulation — a high-dose, long-acting injectable progestin — is allegedly more dangerous than necessary given alternative contraceptives without the same risk. - **Negligence:** failure to exercise reasonable care in testing, monitoring, and communicating risks. ## Who qualifies for a Depo-Provera meningioma lawsuit: screening criteria - **Depo-Provera use:** the claimant received MPA injections; most litigation focuses on use for one year or longer. - **Meningioma diagnosis:** confirmed intracranial meningioma via MRI or CT imaging and/or surgical pathology. - **Temporal relationship:** diagnosis during or after the period of use. Meningiomas diagnosed before use began generally do not qualify. - **Treatment required:** surgical removal, radiation therapy, or ongoing monitoring with documented symptoms. Surgery cases are the strongest. ### Strongest case profiles - Multiple years of use (three or more years is the highest risk tier) - Meningiomas requiring craniotomy - Significant post-surgical complications or permanent neurological deficits - Younger women (under 50), where baseline risk is lower and attributable risk clearer - Well-documented medical records establishing the use-and-diagnosis timeline - No significant alternative meningioma risk factors ## Damages in Depo-Provera meningioma cases ### Economic damages Neuroimaging, craniotomy, inpatient hospitalization, radiation therapy, often-lifelong follow-up imaging, rehabilitation, seizure-control medications, lost wages during treatment, and — for women with permanent impairment — lost earning capacity over their remaining working lives. ### Non-economic damages Pain and suffering from brain surgery and its aftermath, emotional distress of a brain tumor diagnosis, impact on relationships and family life, cognitive and personality changes, loss of enjoyment of life, and anxiety over recurrence monitoring. ### Potential punitive damages If evidence shows Pfizer or predecessors knew of the risk and withheld it to protect sales, punitive damages may be available where permitted. The disparity between international warnings and the absence of comparable U.S. warnings could be particularly damaging to the defense. ## Case-building strategies for Depo-Provera meningioma attorneys ### Comprehensive medical record review Obtain records from all providers who administered injections, pharmacy dispensing records, all neurological treatment records, and relevant pre-existing history. A thorough timeline of use (start date, end date, injection frequency, gaps) is essential for establishing exposure duration. ### Expert witness selection - **Neuro-oncologists or neurosurgeons:** diagnosis, treatment, prognosis, and functional impact - **Epidemiologists:** the ANSM study and supporting population-level research - **Pharmacologists or endocrinologists:** the progesterone-receptor mechanism - **Regulatory experts:** labeling adequacy and FDA obligations - **Economists and life care planners:** future medical costs and lost earning capacity ### Establishing the warning deficiency Compare the U.S. label with international labels that included meningioma warnings — the contrast between what was communicated to American women and what was communicated elsewhere powerfully illustrates the manufacturer's failure. ## Comparative analysis: Depo-Provera in the mass tort landscape Like the Ozempic/GLP-1 litigation (https://www.masstortmarketingagency.com/mass-tort-leads/ozempic), this involves a widely prescribed medication with emerging evidence of underappreciated risks. Like the Suboxone tooth decay litigation (https://www.masstortmarketingagency.com/mass-tort-leads/suboxone), it involves a manufacturer that continued marketing without adequate warnings as evidence accumulated. What distinguishes Depo-Provera is the severity of the injury (brain tumor) and the strength of the epidemiology (5.6-fold risk increase). Brain tumor cases are inherently high-value due to the seriousness of the diagnosis, the invasiveness of treatment, and lasting neurological impairment — suggesting higher per-case values than many other mass tort areas. ## Frequently asked questions ### What is the connection between Depo-Provera and meningioma brain tumors? Depo-Provera contains medroxyprogesterone acetate, a synthetic progestin that binds to progesterone receptors expressed on meningeal cells. Prolonged exposure stimulates meningeal cell growth, which can lead to meningioma. The French ANSM study found women who used Depo-Provera for one year or longer had a 5.6 times higher risk of developing meningioma requiring surgery compared to non-users. ### Who qualifies for a Depo-Provera meningioma lawsuit? Women who received Depo-Provera injections and were subsequently diagnosed with intracranial meningioma. The strongest cases involve one year or more of use, meningioma requiring surgical intervention, and well-documented medical records establishing both the drug use and the diagnosis. ### What is the current status of Depo-Provera meningioma litigation? The litigation is in its early stages, with cases filed in federal and state courts. MDL consolidation proceedings are underway or anticipated. The case inventory is growing as awareness of the link increases among the legal and medical communities. ### How much could a Depo-Provera meningioma case be worth? No settlements have been established yet, but the severity of brain tumor injuries, the invasiveness of treatment (brain surgery), and the potential for lasting neurological deficits suggest significant individual case values. Cases requiring craniotomy with permanent deficits are expected to fall in the higher value tiers once settlement frameworks are established. ### What evidence do I need for a Depo-Provera meningioma claim? Pharmacy or medical records confirming injections (dates and duration), neuroimaging showing the meningioma, neurosurgical records if surgery was performed, pathology reports (especially progesterone receptor status), and documentation of symptoms and their impact on daily life and work capacity. ### Did the FDA issue a warning about Depo-Provera and meningioma? The FDA has been evaluating the evidence and has issued safety communications on the topic. International regulators — particularly in France — have gone further, mandating specific meningioma warnings on the drug label. Plaintiffs argue the manufacturer should have proactively added meningioma warnings even without an explicit FDA mandate. ### Can I still file a Depo-Provera meningioma lawsuit if I used the drug years ago? Potentially, yes. Because the link has only recently been widely recognized, the discovery rule in many states may toll the statute of limitations until the claimant learned or should have learned of the connection. Statutes vary by state, so consult an attorney promptly. ### How can my law firm acquire Depo-Provera meningioma cases? Through digital marketing targeting women who used Depo-Provera, outreach to brain tumor patient support communities, referral networks with gynecologists and neurologists, and partnerships with specialized Depo-Provera mass tort lead generation providers that pre-screen claimants against qualification criteria (https://www.masstortmarketingagency.com/mass-tort-leads/depo-provera).